Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule systems for colorectal cancer screening. Check Cap Ltd develops C-Scan, a patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. Its capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps and other structural abnormalities. C-Scan is a non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
최신 재무제표(Form-10K)에 따르면, Check Cap Ltd의 총 자산은 $0이며, 순손실입니다.
MBAI의 주요 재무 비율은 무엇인가요?
Check Cap Ltd의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Check Cap Ltd의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Check Cap Ltd 주요 수익원은 Investment and Related Activities이며, 최신 수익 발표에서 수익은 28,532,000입니다. 지역별로는 United States이 Check Cap Ltd의 주요 시장이며, 수익은 28,532,000입니다.